The Magazine for Sleep Professionals
Wednesday, July 29, 2026
People who shortened their sleep by around 80 minutes a night for six weeks gained weight—one pound on average—and were more sedentary, researchers at Columbia University Vagelos College of Physicians and Surgeons have found. “Our study shows that getting adequate sleep may help reduce the risk of weight gain and obesity-related […]
Addex Therapeutics announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 […]
Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]
Evaluating the efficacy of a virtual care model using mandibular advancement devices for mild to moderate obstructive sleep apnea By Steven Alvarado, Peter Balacky, DDS, Edward Kim, Daniel Moradzadeh, Julieanna Gonzalez, and Martin L. Hopp, MD, PhD A prevalent sleep disorder affecting an estimated 54 million people in the […]
New survey results from the American Academy of Sleep Medicine explore the complex relationship between marijuana use and sleep. One-third (33%) of adults reported that their sleep is slightly or significantly better when they use marijuana. In contrast, 19% of adults reported either no impact (11%) or that their sleep is […]
Staying active is known to improve sleep, but the research findings are mixed regarding the best workout. Some studies say light walking or stretching is best, others prefer moderate-intensity workouts like jogging — and some even find that vigorous exercise such as swimming makes sleep worse. Resolving this discrepancy is […]
Alkermes plc presents new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of Neurology (AAN) 2026 Annual Meeting, taking place April 18-22, 2026 in Chicago. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment […]
Many more people work very early morning shifts than overnight ones, and a large proportion struggle with excessive sleepiness from shift work disorder, leading to problems with focus, performance and safety. A new clinical trial by investigators from Mass General Brigham found that the wake-promoting drug solriamfetol (Sunosi) helped early […]
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
